nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexfenfluramine—CYP2A6—Methoxsalen—psoriasis	0.185	0.197	CbGbCtD
Dexfenfluramine—CYP1A2—Clobetasol propionate—psoriasis	0.134	0.143	CbGbCtD
Dexfenfluramine—CYP2A6—Prednisolone—psoriasis	0.0897	0.0956	CbGbCtD
Dexfenfluramine—CYP1A2—Methoxsalen—psoriasis	0.0705	0.075	CbGbCtD
Dexfenfluramine—CYP2D6—Hydroxyurea—psoriasis	0.0635	0.0676	CbGbCtD
Dexfenfluramine—CYP2A6—Dexamethasone—psoriasis	0.0529	0.0563	CbGbCtD
Dexfenfluramine—CYP2C19—Cholecalciferol—psoriasis	0.0506	0.0539	CbGbCtD
Dexfenfluramine—CYP2C9—Cholecalciferol—psoriasis	0.0421	0.0448	CbGbCtD
Dexfenfluramine—CYP2D6—Cholecalciferol—psoriasis	0.0385	0.0409	CbGbCtD
Dexfenfluramine—CYP2C19—Prednisone—psoriasis	0.0351	0.0373	CbGbCtD
Dexfenfluramine—CYP2E1—Dexamethasone—psoriasis	0.0349	0.0372	CbGbCtD
Dexfenfluramine—CYP2C19—Cyclosporine—psoriasis	0.0332	0.0354	CbGbCtD
Dexfenfluramine—CYP2C9—Cyclosporine—psoriasis	0.0276	0.0294	CbGbCtD
Dexfenfluramine—CYP2D6—Cyclosporine—psoriasis	0.0253	0.0269	CbGbCtD
Dexfenfluramine—CYP2C19—Dexamethasone—psoriasis	0.0219	0.0233	CbGbCtD
Dexfenfluramine—CYP2C9—Dexamethasone—psoriasis	0.0182	0.0194	CbGbCtD
Dexfenfluramine—CYP2D6—Dexamethasone—psoriasis	0.0166	0.0177	CbGbCtD
Dexfenfluramine—CYP2A6—CYP2E1 reactions—CYP2S1—psoriasis	0.00439	0.0721	CbGpPWpGaD
Dexfenfluramine—CYP2E1—CYP2E1 reactions—CYP2S1—psoriasis	0.00347	0.057	CbGpPWpGaD
Dexfenfluramine—CYP2A6—Xenobiotics—CYP2S1—psoriasis	0.00272	0.0447	CbGpPWpGaD
Dexfenfluramine—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00268	0.044	CbGpPWpGaD
Dexfenfluramine—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00246	0.0404	CbGpPWpGaD
Dexfenfluramine—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00244	0.0401	CbGpPWpGaD
Dexfenfluramine—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.0023	0.0377	CbGpPWpGaD
Dexfenfluramine—CYP2E1—Xenobiotics—CYP2S1—psoriasis	0.00215	0.0353	CbGpPWpGaD
Dexfenfluramine—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.00166	0.0273	CbGpPWpGaD
Dexfenfluramine—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.00153	0.0251	CbGpPWpGaD
Dexfenfluramine—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.00151	0.0249	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.00129	0.0212	CbGpPWpGaD
Dexfenfluramine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00113	0.0186	CbGpPWpGaD
Dexfenfluramine—CYP2A6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00112	0.0183	CbGpPWpGaD
Dexfenfluramine—CYP2A6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000916	0.015	CbGpPWpGaD
Dexfenfluramine—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000893	0.0147	CbGpPWpGaD
Dexfenfluramine—CYP2E1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000881	0.0145	CbGpPWpGaD
Dexfenfluramine—CYP2E1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000724	0.0119	CbGpPWpGaD
Dexfenfluramine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000708	0.0116	CbGpPWpGaD
Dexfenfluramine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000689	0.0113	CbGpPWpGaD
Dexfenfluramine—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00068	0.0112	CbGpPWpGaD
Dexfenfluramine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000634	0.0104	CbGpPWpGaD
Dexfenfluramine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000628	0.0103	CbGpPWpGaD
Dexfenfluramine—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000625	0.0103	CbGpPWpGaD
Dexfenfluramine—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00062	0.0102	CbGpPWpGaD
Dexfenfluramine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000559	0.00917	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000537	0.00882	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00053	0.0087	CbGpPWpGaD
Dexfenfluramine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000514	0.00844	CbGpPWpGaD
Dexfenfluramine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000509	0.00837	CbGpPWpGaD
Dexfenfluramine—CYP2A6—Biological oxidations—CYP2S1—psoriasis	0.000487	0.00799	CbGpPWpGaD
Dexfenfluramine—SLC6A4—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000475	0.0078	CbGpPWpGaD
Dexfenfluramine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000469	0.00771	CbGpPWpGaD
Dexfenfluramine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000452	0.00742	CbGpPWpGaD
Dexfenfluramine—HTR2B—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00045	0.00739	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000435	0.00715	CbGpPWpGaD
Dexfenfluramine—SLC6A4—NRF2 pathway—TGFA—psoriasis	0.000426	0.00699	CbGpPWpGaD
Dexfenfluramine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00041	0.00674	CbGpPWpGaD
Dexfenfluramine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.00041	0.00673	CbGpPWpGaD
Dexfenfluramine—CYP2E1—Biological oxidations—CYP2S1—psoriasis	0.000385	0.00632	CbGpPWpGaD
Dexfenfluramine—CYP2E1—Metapathway biotransformation—CYP2S1—psoriasis	0.000379	0.00623	CbGpPWpGaD
Dexfenfluramine—SLC6A4—SIDS Susceptibility Pathways—IL13—psoriasis	0.000375	0.00616	CbGpPWpGaD
Dexfenfluramine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000363	0.00596	CbGpPWpGaD
Dexfenfluramine—HTR2B—GPCR ligand binding—HCAR2—psoriasis	0.000343	0.00563	CbGpPWpGaD
Dexfenfluramine—CYP2E1—Tryptophan metabolism—CAT—psoriasis	0.000332	0.00545	CbGpPWpGaD
Dexfenfluramine—SLC6A4—Monoamine Transport—TNF—psoriasis	0.000317	0.00521	CbGpPWpGaD
Dexfenfluramine—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000297	0.00487	CbGpPWpGaD
Dexfenfluramine—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000293	0.00481	CbGpPWpGaD
Dexfenfluramine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000289	0.00474	CbGpPWpGaD
Dexfenfluramine—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000288	0.00473	CbGpPWpGaD
Dexfenfluramine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000286	0.0047	CbGpPWpGaD
Dexfenfluramine—HTR2C—GPCR ligand binding—HCAR2—psoriasis	0.000276	0.00454	CbGpPWpGaD
Dexfenfluramine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000273	0.00448	CbGpPWpGaD
Dexfenfluramine—CYP2A6—NRF2 pathway—TGFA—psoriasis	0.000271	0.00445	CbGpPWpGaD
Dexfenfluramine—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000271	0.00444	CbGpPWpGaD
Dexfenfluramine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000269	0.00442	CbGpPWpGaD
Dexfenfluramine—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000267	0.00438	CbGpPWpGaD
Dexfenfluramine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000265	0.00435	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000263	0.00432	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000258	0.00423	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000247	0.00405	CbGpPWpGaD
Dexfenfluramine—SLC6A4—SIDS Susceptibility Pathways—IL10—psoriasis	0.000235	0.00385	CbGpPWpGaD
Dexfenfluramine—HTR2B—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000234	0.00384	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000231	0.0038	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000228	0.00375	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000228	0.00374	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000224	0.00368	CbGpPWpGaD
Dexfenfluramine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000201	0.0033	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000199	0.00328	CbGpPWpGaD
Dexfenfluramine—HTR2B—GPCR downstream signaling—HCAR2—psoriasis	0.000194	0.00318	CbGpPWpGaD
Dexfenfluramine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000189	0.0031	CbGpPWpGaD
Dexfenfluramine—HTR2B—GPCR ligand binding—CCL20—psoriasis	0.000178	0.00292	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling by GPCR—HCAR2—psoriasis	0.000176	0.00289	CbGpPWpGaD
Dexfenfluramine—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	0.000174	0.00285	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000172	0.00282	CbGpPWpGaD
Dexfenfluramine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	0.000171	0.00281	CbGpPWpGaD
Dexfenfluramine—SLC6A4—Circadian rythm related genes—LEP—psoriasis	0.000158	0.00259	CbGpPWpGaD
Dexfenfluramine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	0.000157	0.00258	CbGpPWpGaD
Dexfenfluramine—HTR2C—GPCR downstream signaling—HCAR2—psoriasis	0.000156	0.00257	CbGpPWpGaD
Dexfenfluramine—SLC6A4—Circadian rythm related genes—NOS2—psoriasis	0.000147	0.00241	CbGpPWpGaD
Dexfenfluramine—HTR2C—GPCR ligand binding—CCL20—psoriasis	0.000144	0.00236	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling by GPCR—HCAR2—psoriasis	0.000142	0.00233	CbGpPWpGaD
Dexfenfluramine—SLC6A4—Circadian rythm related genes—PPARG—psoriasis	0.000137	0.00225	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	0.000133	0.00219	CbGpPWpGaD
Dexfenfluramine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.000128	0.00211	CbGpPWpGaD
Dexfenfluramine—SLC6A4—SIDS Susceptibility Pathways—JUN—psoriasis	0.000119	0.00196	CbGpPWpGaD
Dexfenfluramine—SLC6A4—SIDS Susceptibility Pathways—NFKB1—psoriasis	0.000115	0.00189	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000111	0.00182	CbGpPWpGaD
Dexfenfluramine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—psoriasis	0.000104	0.00171	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling Pathways—HCAR2—psoriasis	0.000104	0.00171	CbGpPWpGaD
Dexfenfluramine—HTR2B—GPCR downstream signaling—CCL20—psoriasis	0.000101	0.00165	CbGpPWpGaD
Dexfenfluramine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	9.79e-05	0.00161	CbGpPWpGaD
Dexfenfluramine—CYP2A6—Metabolism—NDUFA5—psoriasis	9.79e-05	0.00161	CbGpPWpGaD
Dexfenfluramine—SLC6A4—Circadian rythm related genes—JUN—psoriasis	9.73e-05	0.0016	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	9.57e-05	0.00157	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	9.22e-05	0.00151	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling by GPCR—CCL20—psoriasis	9.13e-05	0.0015	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling Pathways—TAGAP—psoriasis	9.01e-05	0.00148	CbGpPWpGaD
Dexfenfluramine—SLC6A4—SIDS Susceptibility Pathways—TNF—psoriasis	8.93e-05	0.00147	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling Pathways—HCAR2—psoriasis	8.38e-05	0.00138	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	8.36e-05	0.00137	CbGpPWpGaD
Dexfenfluramine—CYP2A6—Metabolism—CYP2S1—psoriasis	8.32e-05	0.00137	CbGpPWpGaD
Dexfenfluramine—HTR2C—GPCR downstream signaling—CCL20—psoriasis	8.12e-05	0.00133	CbGpPWpGaD
Dexfenfluramine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	7.9e-05	0.0013	CbGpPWpGaD
Dexfenfluramine—CYP2E1—Metabolism—NDUFA5—psoriasis	7.73e-05	0.00127	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling by GPCR—CCL20—psoriasis	7.37e-05	0.00121	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling Pathways—TAGAP—psoriasis	7.27e-05	0.00119	CbGpPWpGaD
Dexfenfluramine—SLC6A4—SIDS Susceptibility Pathways—IL6—psoriasis	7.2e-05	0.00118	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	7.17e-05	0.00118	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	7.17e-05	0.00118	CbGpPWpGaD
Dexfenfluramine—CYP2E1—Metabolism—CYP2S1—psoriasis	6.58e-05	0.00108	CbGpPWpGaD
Dexfenfluramine—SLC6A4—Circadian rythm related genes—TP53—psoriasis	6.43e-05	0.00106	CbGpPWpGaD
Dexfenfluramine—HTR2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	6.31e-05	0.00104	CbGpPWpGaD
Dexfenfluramine—CYP2C19—Metabolism—NDUFA5—psoriasis	5.97e-05	0.00098	CbGpPWpGaD
Dexfenfluramine—SLC6A4—Circadian rythm related genes—IL6—psoriasis	5.88e-05	0.000966	CbGpPWpGaD
Dexfenfluramine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.56e-05	0.000914	CbGpPWpGaD
Dexfenfluramine—CYP2D6—Metabolism—NDUFA5—psoriasis	5.49e-05	0.000902	CbGpPWpGaD
Dexfenfluramine—CYP2C9—Metabolism—NDUFA5—psoriasis	5.44e-05	0.000894	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling Pathways—CCL20—psoriasis	5.4e-05	0.000886	CbGpPWpGaD
Dexfenfluramine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	5.09e-05	0.000836	CbGpPWpGaD
Dexfenfluramine—CYP2C19—Metabolism—CYP2S1—psoriasis	5.07e-05	0.000833	CbGpPWpGaD
Dexfenfluramine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.07e-05	0.000833	CbGpPWpGaD
Dexfenfluramine—HTR2B—GPCR ligand binding—CXCL8—psoriasis	4.81e-05	0.00079	CbGpPWpGaD
Dexfenfluramine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	4.79e-05	0.000787	CbGpPWpGaD
Dexfenfluramine—CYP2D6—Metabolism—CYP2S1—psoriasis	4.67e-05	0.000767	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Metabolism—NDUFA5—psoriasis	4.65e-05	0.000764	CbGpPWpGaD
Dexfenfluramine—CYP2C9—Metabolism—CYP2S1—psoriasis	4.63e-05	0.00076	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling Pathways—CCL20—psoriasis	4.35e-05	0.000715	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.34e-05	0.000712	CbGpPWpGaD
Dexfenfluramine—CYP2A6—Metabolism—CARM1—psoriasis	4.06e-05	0.000668	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Metabolism—CYP2S1—psoriasis	3.95e-05	0.000649	CbGpPWpGaD
Dexfenfluramine—HTR2C—GPCR ligand binding—CXCL8—psoriasis	3.88e-05	0.000637	CbGpPWpGaD
Dexfenfluramine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	3.86e-05	0.000635	CbGpPWpGaD
Dexfenfluramine—CYP2E1—Metabolism—CARM1—psoriasis	3.21e-05	0.000528	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling Pathways—SOCS1—psoriasis	2.97e-05	0.000488	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling by GPCR—TYK2—psoriasis	2.83e-05	0.000465	CbGpPWpGaD
Dexfenfluramine—HTR2B—GPCR downstream signaling—CXCL8—psoriasis	2.72e-05	0.000446	CbGpPWpGaD
Dexfenfluramine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.66e-05	0.000437	CbGpPWpGaD
Dexfenfluramine—CYP2A6—Metabolism—CAT—psoriasis	2.5e-05	0.000411	CbGpPWpGaD
Dexfenfluramine—CYP2C19—Metabolism—CARM1—psoriasis	2.48e-05	0.000407	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling by GPCR—CXCL8—psoriasis	2.47e-05	0.000405	CbGpPWpGaD
Dexfenfluramine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.42e-05	0.000398	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling Pathways—SOCS1—psoriasis	2.4e-05	0.000394	CbGpPWpGaD
Dexfenfluramine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.32e-05	0.00038	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling by GPCR—TYK2—psoriasis	2.29e-05	0.000375	CbGpPWpGaD
Dexfenfluramine—CYP2D6—Metabolism—CARM1—psoriasis	2.28e-05	0.000374	CbGpPWpGaD
Dexfenfluramine—CYP2C9—Metabolism—CARM1—psoriasis	2.26e-05	0.000371	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling Pathways—APOE—psoriasis	2.19e-05	0.00036	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling Pathways—LEP—psoriasis	2.19e-05	0.00036	CbGpPWpGaD
Dexfenfluramine—HTR2C—GPCR downstream signaling—CXCL8—psoriasis	2.19e-05	0.00036	CbGpPWpGaD
Dexfenfluramine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.11e-05	0.000347	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.07e-05	0.00034	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling Pathways—NFKBIA—psoriasis	2.04e-05	0.000336	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling by GPCR—CXCL8—psoriasis	1.99e-05	0.000327	CbGpPWpGaD
Dexfenfluramine—CYP2E1—Metabolism—CAT—psoriasis	1.98e-05	0.000324	CbGpPWpGaD
Dexfenfluramine—CYP2A6—Metabolism—APOE—psoriasis	1.94e-05	0.000319	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Metabolism—CARM1—psoriasis	1.93e-05	0.000317	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.8e-05	0.000296	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling Pathways—APOE—psoriasis	1.77e-05	0.000291	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling Pathways—LEP—psoriasis	1.77e-05	0.000291	CbGpPWpGaD
Dexfenfluramine—CYP2A6—Metabolism—PPARG—psoriasis	1.69e-05	0.000278	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling Pathways—TYK2—psoriasis	1.67e-05	0.000275	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling Pathways—NFKBIA—psoriasis	1.65e-05	0.000271	CbGpPWpGaD
Dexfenfluramine—CYP2E1—Metabolism—APOE—psoriasis	1.53e-05	0.000252	CbGpPWpGaD
Dexfenfluramine—CYP2C19—Metabolism—CAT—psoriasis	1.52e-05	0.00025	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling Pathways—CXCL8—psoriasis	1.46e-05	0.000239	CbGpPWpGaD
Dexfenfluramine—CYP2D6—Metabolism—CAT—psoriasis	1.4e-05	0.00023	CbGpPWpGaD
Dexfenfluramine—CYP2C9—Metabolism—CAT—psoriasis	1.39e-05	0.000228	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling by GPCR—IL6—psoriasis	1.39e-05	0.000228	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling Pathways—JUN—psoriasis	1.35e-05	0.000223	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling Pathways—TYK2—psoriasis	1.35e-05	0.000222	CbGpPWpGaD
Dexfenfluramine—CYP2E1—Metabolism—PPARG—psoriasis	1.34e-05	0.00022	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling Pathways—NFKB1—psoriasis	1.3e-05	0.000214	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Metabolism—CAT—psoriasis	1.19e-05	0.000195	CbGpPWpGaD
Dexfenfluramine—CYP2C19—Metabolism—APOE—psoriasis	1.18e-05	0.000195	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling Pathways—VEGFA—psoriasis	1.18e-05	0.000194	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling Pathways—CXCL8—psoriasis	1.18e-05	0.000193	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling Pathways—STAT3—psoriasis	1.17e-05	0.000192	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling by GPCR—IL6—psoriasis	1.12e-05	0.000184	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling Pathways—JUN—psoriasis	1.09e-05	0.00018	CbGpPWpGaD
Dexfenfluramine—CYP2D6—Metabolism—APOE—psoriasis	1.09e-05	0.000179	CbGpPWpGaD
Dexfenfluramine—CYP2C9—Metabolism—APOE—psoriasis	1.08e-05	0.000177	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling Pathways—NFKB1—psoriasis	1.05e-05	0.000173	CbGpPWpGaD
Dexfenfluramine—CYP2C19—Metabolism—PPARG—psoriasis	1.03e-05	0.000169	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling Pathways—VEGFA—psoriasis	9.55e-06	0.000157	CbGpPWpGaD
Dexfenfluramine—CYP2D6—Metabolism—PPARG—psoriasis	9.49e-06	0.000156	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling Pathways—STAT3—psoriasis	9.45e-06	0.000155	CbGpPWpGaD
Dexfenfluramine—CYP2C9—Metabolism—PPARG—psoriasis	9.4e-06	0.000154	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Metabolism—APOE—psoriasis	9.23e-06	0.000152	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling Pathways—TP53—psoriasis	8.94e-06	0.000147	CbGpPWpGaD
Dexfenfluramine—HTR2B—Signaling Pathways—IL6—psoriasis	8.19e-06	0.000134	CbGpPWpGaD
Dexfenfluramine—CYP1A2—Metabolism—PPARG—psoriasis	8.04e-06	0.000132	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling Pathways—TP53—psoriasis	7.21e-06	0.000119	CbGpPWpGaD
Dexfenfluramine—HTR2C—Signaling Pathways—IL6—psoriasis	6.6e-06	0.000108	CbGpPWpGaD
